Live Analyst Rating Changes 20533 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Serge Belanger
NDM

Serge Belanger

Needham
Wall Street Analyst
★★★☆☆
#1193
on 13Foresight · ranked by our own returns
52%
Success Rate
+6.0%
Average Return
26 of 50 calls profitable · +4.5% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 52% of Serge Belanger's ratings turned a profit when each position was held for 1 year — averaging +6.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

156 Buy 34 Hold 0 Sell
Serge's Stock Coverage 25 ratings · 2026-08-08
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CYTK
Cytokinetics
 Aug 07, 2026 BUY Strong Buy
+16.3% avg upside
36 analysts
$112.00
45.84% Upside
 +0.0% ·
OCS
Oculis Holding
 Aug 07, 2026 BUY Strong Buy
+198.8% avg upside
11 analysts
$38.00
199.59% Upside
 · ·
NAMS
NewAmsterdam Pharma Company
 Aug 07, 2026 BUY Strong Buy
+70.7% avg upside
19 analysts
$48.00
71.64% Upside
 +0.0% ·
TRVI
Trevi Therapeutics
 Aug 07, 2026 BUY Strong Buy
+30.6% avg upside
18 analysts
$23.00
24.21% Upside
 +0.0% ·
VRCA
Verrica Pharmaceuticals
 Aug 07, 2026 HOLD Strong Buy
+260.5% avg upside
8 analysts
 — · ·
XENE
Xenon
 Aug 07, 2026 BUY Strong Buy
-1.9% avg upside
28 analysts
$78.00
23.01% Upside
 +0.0% ·
AMPH
Amphastar Pharmaceuticals
 Aug 07, 2026 HOLD Hold
+24.7% avg upside
11 analysts
$20.00
3.85% Downside
 · ·
COLL
Collegium Pharmaceutical
 Aug 06, 2026 BUY Strong Buy
+38.4% avg upside
8 analysts
$46.00
56.19% Upside
 +1.2% ·
ARQT
Arcutis Biotherapeutics
 Aug 06, 2026 BUY Strong Buy
+57.2% avg upside
14 analysts
$40.00
58.20% Upside
 -3.1% ·
EOLS
Evolus
 Aug 06, 2026 HOLD Strong Buy
+92.9% avg upside
9 analysts
 — · ·
VRDN
Viridian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+50.3% avg upside
32 analysts
$34.00
44.23% Upside
 +4.8% ·
BCRX
BioCryst
 Aug 05, 2026 BUY Strong Buy
+93.4% avg upside
24 analysts
$16.00
70.56% Upside
 · ·
PCRX
Pacira Pharmaceuticals
 Aug 05, 2026 BUY Buy
+55.6% avg upside
21 analysts
$33.00
31.89% Upside
 +2.9% ·
OCUL
Ocular Therapeutix
 Aug 03, 2026 BUY Strong Buy
+169.6% avg upside
21 analysts
$18.00
95.81% Upside
 +9.4% ·
OMER
Omeros
 Jul 27, 2026 HOLD Buy
+58.0% avg upside
14 analysts
 — +16.8% ·
MANE
Veradermics, Incorporated
 Jul 15, 2026 BUY Strong Buy
+34.2% avg upside
7 analysts
$164.00
43.42% Upside
 -7.5% ·
MLTX
MoonLake Immunotherapeutics
 Jun 22, 2026 BUY Strong Buy
+59.7% avg upside
20 analysts
$30.00
64.31% Upside
 -62.3% ·
HRTX
Heron Therapeutics
 Jun 02, 2026 HOLD Strong Buy
+5430.9% avg upside
21 analysts
 — +9.1% ·
CRMD
Cormedix
 May 14, 2026 BUY Strong Buy
+100.3% avg upside
13 analysts
$15.00
101.63% Upside
 -5.2% ·
LQDA
Liquidia Technologies
 May 11, 2026 BUY Strong Buy
-30.0% avg upside
15 analysts
$70.00
22.46% Downside
 +69.8% ·
AKBA
Akebia Therapeutics
 Oct 28, 2022 HOLD Strong Buy
+929.5% avg upside
16 analysts
 — +223.1% ·
CALC
CalciMedica
 Oct 28, 2022 HOLD Buy
+4030.4% avg upside
9 analysts
 — · ·
VIP
Vulcan Infrastructure and Power
 Nov 05, 2021 BUY Hold
+381.7% avg upside
5 analysts
$22.00
973.15% Upside
 · ·
EVFM
Evofem Biosciences
 Jun 26, 2017 HOLD Buy
+272685.7% avg upside
8 analysts
 — · ·
CYTOF
Altamira Therapeutics
 Aug 19, 2016 BUY Strong Buy
+28338.7% avg upside
4 analysts
$5.00
7899.97% Upside
 · ·
🔒 20 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Serge Belanger — Frequently Asked Questions
How accurate are Serge Belanger's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Serge's ratings were profitable over a one-year hold, with an average return of +6.0% per rating, or +4.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Serge ranked on 13Foresight?
Serge Belanger is currently ranked #1193 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Serge cover?
Serge most recently has ratings on CYTK, OCS, NAMS, TRVI, VRCA, XENE, AMPH, COLL, ARQT, EOLS, VRDN, BCRX and 13 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.